Close Menu

InterWest Partners

Bruker said this week it has appointed Joshua Young vice president of investor relations. Young will take over from Stacey Desrochers, who will focus on management of the company's treasury operations.

The company next year plans to launch a 1,000-patient verification trial for its lung cancer protein biomarker panel, with trials for its Alzheimer's disease panel likely to follow, said an official.

The molecular diagnostics company plans to use the funds for marketing and R&D.

Lycera, which is developing drugs for autoimmune diseases, will use the cash to advance through Phase II proof-of-concept studies a drug based on University of Michigan research, and into Phase I trials a second candidate based on research conducted at New York University.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.